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do not develop humoral immunity against  
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Abstract 
Background: Malaria is still one of the most prevalent infectious diseases in the world. Sequestration of infected 
erythrocytes (IEs) is the prime mediator of disease. Cytoadhesion of IEs is mediated by members of the highly diverse 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). A restricted sub‑set of var genes encoding for 
PfEMP1s possessing the domain cassettes DC8 and DC13 were found to bind to the endothelial protein C receptor 
(EPCR). These var genes were shown to be highly expressed by parasites from patients with severe malaria clinical 
outcomes compared to those from patients with uncomplicated symptoms.
Methods: In order to further study the molecular mechanisms underlying DC8/DC13 expressing IEs adhesion to 
EPCR, a method was developed to produce highly pure recombinant EPCR. The IT4 parasite strain was selected on 
either anti‑IT4‑VAR19 purified IgG, EPCR or human brain endothelial cell line and their var gene expression profiles as 
well as their binding phenotypes were compared. The N‑terminal region of IT4‑VAR19 comprising a full‑length DC8 
cassette as well as the single EPCR binding CIDRα1.1 domain were also produced, and their immune recognition (IgG) 
was assessed using plasma samples from Beninese children presenting acute mild malaria, severe malaria or cerebral 
malaria at the time of their admission to the clinic, and from convalescent‑phase plasma collected 30 days after anti‑
malarial treatment.
Results: The multi‑domain VAR19‑NTS‑DBLγ6 binds to EPCR with a greater affinity than the CIDRα1.1 domain alone 
and this study also demonstrates that VAR19‑NTS‑DBLγ6 binding to the EPCR‑expressing endothelial cell line (HBEC5i) 
is more pronounced than that of the CIDRα1.1 domain alone. IT4‑VAR19 represents the preferentially expressed‑
PfEMP1 when FCR3‑IEs are selected based on their capability to bind EPCR. Notably, no significant difference in the 
levels of antibodies towards IT4‑VAR19 antigens was observed within all clinical groups between plasma samples col‑
lected during the acute malaria phase compared to samples collected 30 days after anti‑malaria treatment.
Conclusions: These data indicate that even being the preferentially selected IT4‑EPCR‑binding variant, the IT4‑
VAR19‑DC8 region does not appear to be associated with the acquisition of antibodies during a single severe paediat‑
ric malaria episode in Benin.
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Background
Malaria is still one of the most prevalent infectious dis-
eases in the world, affecting 198 million individuals 
per year and causing an estimated 584,000 subsequent 
deaths, mostly in children aged under 5  years account-
ing for 78 % of all deaths [1]. Plasmodium falciparum is 
responsible for the most severe malaria cases and fatal 
conditions. P. falciparum has developed an efficient 
immune evasion strategy in which antigenic variation 
associated with cytoadhesion mechanisms play a central 
role.
Indeed, the ability of P. falciparum infected erythro-
cytes (IEs) to adhere to host receptors, such as CD36, 
chondroitin sulfate A (CSA) and ICAM-1 present on the 
surface of microvascular endothelial cells or on the syn-
cytiotrophoblast lining the intervillous placental blood 
space [2], allows IE sequestration and prevents IE tran-
sit through the spleen’s red pulp and their subsequent 
retention and clearance [3, 4]. Sequestration is the prime 
mediator of disease, creating blood flow obstructions and 
damage to the endothelial barrier, inducing a cascade of 
inflammatory and coagulation pathways [2].
Cytoadhesion of IEs is mediated by members of the 
highly diverse P. falciparum erythrocyte membrane pro-
tein 1 (PfEMP1) encoded by approximately 60 var genes 
per parasite genome [5, 6]. A single var gene is expressed 
at a time and the corresponding PfEMP1 is exported 
at the IE’s surface. Switching between variants allows 
the exposure of different antigenic determinants to the 
immune system and rapid changes in IE receptor tropism 
[6, 7].
Although the var repertoires are highly divergent, 
genes can be classified into three main groups (A, B and 
C) and two intermediate groups B/A and B/C based on 
their upstream promoter sequence (Ups), their chromo-
somal location/transcriptional direction and their coding 
region organization [8, 9]. All PfEMP1 variants display a 
N-terminal segment (NTS) followed by successive Duffy-
binding-like (DBL) and cysteine-rich interdomain region 
(CIDR) domains [10]. Analysis of almost 400 PfEMP1 
sequences revealed conserved domain structures permit-
ting a sub-division of these putative functional groups 
into 18 well-defined domain cassettes (apart from var3, 
var1csa and var2csa which are relatively conserved 
between different parasite genomes) [11].
Recently, a small sub-set of chimeric var genes belong-
ing to the group B/A (group B Ups and group A coding 
sequences) has been linked to cerebral malaria. Indeed, 
IEs expressing these genes were preferentially selected 
after consecutive panning rounds either on the human 
brain endothelial cell line HBEC-5i or on primary culture 
of human brain microvascular endothelial cells [12, 13]. 
Furthermore, a restricted sub-set of var genes encoding 
PfEMP1s possessing the domain cassettes (DC) DC8 
and DC13 were found to be expressed at a higher level in 
patients with severe malaria clinical outcomes compared 
to patients presenting uncomplicated symptoms [14].
The DC8 cassette is composed of four domains 
(DBLα2-CIDRα1.1-DBLβ12-DBLγ4/6) whereas DC13 
contains only two domains (DBLα1.7-CIDRα1.4). 
Both DC8 and DC13 expressing IEs have recently been 
shown to bind to a specific receptor on the endothe-
lium, the endothelial protein C receptor (EPCR), via their 
CIDRα1.1 or CIDRα1.4 domain [15]. These non-CD36 
binding PfEMP1 variants were shown to avidly bind to 
diverse brain endothelial cells but also to endothelial cells 
originating from other tissues [16]. Notably, the four indi-
vidual domains from DC8 are able to bind to endothe-
lial cells [16]. Since DC8-CIDRα1.1 is, to date, the only 
EPCR-binding domain of the cassette, these results sug-
gest that DC8-PfEMP1 binding to endothelial cells rely 
on other types of interaction, implicating one or several, 
yet unidentified, receptor(s).
The identification of EPCR as an IEs receptor opened 
new avenues that might help understanding the patho-
genesis of severe malaria. Several studies, sometimes 
conflicting, exploring the link between EPCR and malaria 
pathophysiology, revealed the complexity of how P. falci-
parum may interact with its host.
Autopsies performed on Malawian children who died 
from cerebral malaria exposed a loss of EPCR in cer-
ebral microvessels at the site of IE sequestration [17]. 
This might at first appear contradictory with the poten-
tial role of EPCR as a major anchor point for IEs in the 
brain, but the precise sequence of events leading to the 
post-mortem observations remains unknown. EPCR pro-
motes cytoprotection and anti-inflammatory signaling in 
a variety of cell types via its interactions with activated 
protein C (APC) [18]. The local loss of EPCR may, there-
fore, implicate coagulation and inflammation at the IE 
sequestration site, leading to a detrimental outcome. Fur-
thermore, DC8-PfEMP1 has been shown to compete the 
binding of APC to EPCR [15], most likely exacerbating 
the inflammatory cascades.
A recent study showed that Thai malaria patients car-
rying a mutation in the PROCR gene that leads to higher 
levels of soluble EPCR in the plasma, were significantly 
protected against severe malaria compared to other 
PROCR genotypes [19]. Nevertheless, some contrasting 
data suggest that genetic diversity in the PROCR gene is 
not linked with severe malaria outcome in Ghanaian chil-
dren [20] and that high plasma levels of soluble EPCR are 
associated with increased mortality in children in Benin 
[21].
In this context, it is evident that additional work is 
needed to understand the clinical consequences of IE 
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binding to EPCR and to decipher the detailed cooperative 
molecular mechanisms (including sequestration, inflam-
mation, coagulation) implicated in childhood cerebral 
malaria and their relative importance in disease severity.
The PfEMP1  N-terminal region appears to have an 
important role in IE cytoadhesion, but it is not clear 
if all DC8 cassettes present the same binding proper-
ties, nor if different EPCR-binding IEs have equivalent 
severe disease potential. Sequestration may be mediated 
by a multi-adhesive phenomenon involving numerous 
endothelial adhesion receptors and parasite ligands in 
order to maximize adhesion.
In this study aiming at assessing the importance of 
DC8/DC13 expressing IEs in EPCR binding, erythro-
cytes infected with the IT parasite strain were selected on 
either anti-PfEMP1 IT4-VAR19 purified IgG, EPCR or on 
the human brain endothelial cell line HBEC-5i and their 
var gene expression profiles as well as their binding phe-
notypes were compared. Furthermore, the N-terminal 
region of PfEMP1 IT4-VAR19 comprising a full-length 
DC8 cassette as well as the single EPCR binding domain 
CIDRα1.1, produced as recombinant proteins, were 
used to analyse their recognitions by plasma IgG from 
Beninese children presenting acute mild malaria, severe 
malaria or cerebral malaria at the time of their admission 
to the clinic and 30  days later. Taken together, the data 
indicate that IT4-VAR19 is the preferentially selected 
IT4-EPCR-binding var gene, but that humoral immunity 
against the EPCR binding VAR19-DC8 cassette or the 
CIDRα1.1 domain is not boosted during a single paediat-
ric severe malaria episode in Benin.
Methods
Expression and purification of recombinant proteins
A synthetic gene sequence encoding the N-terminal 
region of IT4-VAR19 (VAR19-NTS-DBLγ6, residues 
G2-P1713) [Uniprot: A3R6S3] was designed with opti-
mized codon usage for heterologous expression in 
human-based cell lines. This gene was cloned into a 
pTT3 vector with an N-terminal murine Ig κ-chain 
leader sequence and a hexa-His C-terminal tag. VAR19-
NTS-DBLγ6 was produced as a soluble and secreted 
recombinant protein. Expression was carried out in the 
permanent cell line established from primary embryonic 
human kidney, HEK293F (Life Technologies), as already 
described [22]. The protein was purified on a HisTrap 
High Performance Ni-affinity column (GE Healthcare), 
followed by gel filtration chromatography on a Superdex 
200 10/300 GL column (GE Healthcare).
The gene sequence encoding VAR19-CIDRα1.1 (resi-
dues S580-P739, boundaries based on [23]) was ampli-
fied by PCR from IT4 genomic DNA and cloned into a 
modified pET28a vector in which a sequence coding an 
N-terminal HA-tag (YPYDVPDYA) has been inserted 
after the NcoI restriction site. The recombinant VAR19-
CIDRα1.1 protein was expressed in the SHuffle® strain 
(NEB Biolabs) of Escherichia coli as a soluble protein 
after IPTG induction at 20  °C for 20  h. Cells were then 
centrifuged, resuspended in 20  mM Tris–HCl, 150  mM 
NaCl, pH 7.5 and lysed by three successive passages in 
an Emulsiflex homogenizer (Avestin). VAR19-CIDRα1.1 
was purified on a HisTrap High Performance Ni-affinity 
column (GE Healthcare), followed by a gel filtration chro-
matography on a Superdex 200 10/300 GL column (GE 
Healthcare).
The gene encoding soluble EPCR (residues S18-
S210) [Uniprot: Q9UNN8] was amplified by PCR from 
a human lung endothelium cDNA library. The EPCR 
gene sequence was cloned into two different pTT3 
vectors, a pTT3 vector with an N-terminal murine Ig 
κ-chain leader sequence and a hexa-His C-terminal tag 
and a modified pTT3 vector possessing a FLAG tag just 
upstream of the hexa-His C-terminal tag. Both EPCR 
recombinant proteins were produced in HEK293F cells 
[22] and purified on a HisTrap High Performance Ni-
affinity column (GE Healthcare), followed by a gel filtra-
tion chromatography on a HiLoad 16/60 Superdex 75 
column (GE Healthcare).
A qualitative analysis of all recombinant proteins was 
performed by SDS-PAGE (Coomassie blue staining) and 
Western blotting with relevant antibodies.
Human brain endothelial cell culture
The human brain endothelial cell line HBEC5i (CDC, 
Atlanta, USA) was cultured in DMEM/F-12 GlutaMAX 
medium (Gibco) supplemented with 10  % heat-inacti-
vated fetal bovine serum (Gibco), 1X endothelial cell 
growth factor (Sigma) and 10U/ml penicillin/streptomy-
cin (Gibco).
Parasite culture and infected erythrocyte selection
The P. falciparum laboratory adapted parasite line FCR3 
(IT4) was grown in O+ human erythrocytes in RPMI 
1640 medium containing Hepes (25  mM) and l-glu-
tamine (2 mM) (Gibco) supplemented with 5 % Albumax, 
5  % human serum, 0.1  mM hypoxanthine and 20  µg/
ml gentamicin [24]. Parasites were routinely genotyped 
by PCR using MSP1/MSP2 primers [25] and tested for 
potential mycoplasma contamination (LookOut Myco-
plasma PCR Detection Kit by SIGMA). Cultures were 
routinely selected by gelatin flotation using Plasmion 
(Fresenius Kabi) to maintain knob-positive parasites [26]. 
Synchronized parasite cultures (3–6  % parasitaemia) 
at mid/late trophozoite stages were purified using Vari-
oMACS and CS columns (Miltenyi Biotec) as previously 
described [27].
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Erythrocytes infected with FCR3 (IT4) were selected 
for the CSA-binding phenotype by multiple panning 
rounds on CSA. These CSA-binding IEs are referred to as 
FCR3-CSA throughout this paper.
IEs FCR3-VAR19 and FCR3-EPCR were selected on 
purified rabbit anti-IT4-VAR19 antibodies and EPCR, 
respectively. FCR3-CSA was used as the starting culture 
for carrying out the different selection processes. One-
hundred µl of Dynabeads (‘Protein G’ for rabbit antibody 
selection or ‘His-tag Isolation and Pulldown’  for EPCR 
selection) were coated with 20 µg of purified anti-VAR19 
antibodies or 20  µg of EPCR for 10  min, washed twice 
with PBS and blocked with PBS 1  % BSA for 10  min at 
room temperature (RT). Purified IEs at trophozoite stage 
were then allowed to adhere to the coated beads for 
20 min at 37 °C. The unbound IEs were washed out with 
PBS while the bound IEs were isolated using magnetic 
force and brought back into culture dishes. The day after 
panning, the beads were removed from the cultures and 
RNA was extracted for var transcription profile analysis. 
Six to seven rounds of panning were needed to obtain a 
population in which the var gene transcription profile 
did not vary any more, reflecting complete selection for a 
given binding phenotype.
Animal immunization
Immunization with VAR19-NTS-DBLγ6 recombinant 
protein was performed by BIOTEM, France, according 
to animal immunization guidelines. In brief, two New 
Zealand White rabbits received 50  µg of recombinant 
protein in FREUND adjuvant intradermally for the first 
immunization followed by three subcutaneous boosts (at 
day 14, 28 and 42) of 25 µg of protein. Sera were collected 
before immunization (Pre-Immune) and at day 49 and 63 
according to the immunization schedule. IgG were puri-
fied from rabbit sera using HiTrap Protein G High Per-
formance columns (GE Healthcare). Purified antibodies 
were dialyzed against PBS 1X pH 7.2. Antibody titres for 
each sample were determined by ELISA using the immu-
nizing proteins as target antigens. The titres were calcu-
lated using 4-parameter curve fitting and represent the 
serum dilution at which 50 % of the maximum recogni-
tion signal was reached.
ELISA‑based binding inhibition assay
ELISA plates (Nunc) were coated with 100 µl of recom-
binant VAR19-NTS-DBLγ6 protein (10  µg/ml in PBS) 
and incubated overnight at 4 °C. After coating, the wells 
were blocked with PBS 1  % BSA 0.05  % Tween (PBST-
BSA), 150 µl per well at 37 °C for 1 h. After removing the 
blocking solution, serial dilutions of purified anti-VAR19 
antibodies (concentrations ranging from 0.18 to 1.8  µg/
ml diluted in PBST-BSA) were added to the wells and the 
plates were incubated at 37  °C for 1  h. Wells were then 
washed three times with PBST-BSA and 1 µg/ml of EPCR 
was added for 1 h at 37 °C. The wells were washed with 
PBST and EPCR-binding was detected with a HRP-con-
jugated mouse anti-FLAG M2 antibody (Abcam), diluted 
1:2000 in PBST-BSA. Plates were read at 655  nm after 
addition of 100  µl of TMB (3,3′,5,5′-tetramethylbenzi-
dine) substrate per well (Biorad).
Flow cytometry and immuno‑fluorescence assay
Parasite cultures at mid/late trophozoite stages were 
purified using VarioMACS and washed twice with PBS 
0.2 % BSA. For each assay, 0.5 × 106 IEs were incubated 
with purified rabbit anti-IT4-VAR19 and purified anti-
VAR2CSA antibodies [28] diluted 1:100 in PBS 0.2  % 
BSA, and mouse anti-human IgM antibodies (ProMab) 
diluted 1:50 in PBS 0.2  % BSA. After 1-h incubation at 
4 °C, the IEs were washed twice with PBS 0.2 % BSA and 
incubated at 4  °C for 30 min with a PE-conjugated goat 
F(ab’)2 anti-rabbit or anti-mouse IgG (Beckman Coulter, 
diluted 1:100 in PBS 0.2  % BSA). Cells were fixed over-
night with paraformaldehyde (PFA) 4  % and washed 
twice with PBS. Cells were analysed by flow cytometry 
as described below and by confocal microscopy (Zeiss 
LSM700 confocal microscope).
Flow cytometry‑based binding assay
For each assay, 0.5 ×  106 HBEC-5i cells were incubated 
with 100  µg/ml of IT4-VAR19 recombinant proteins 
(VAR19-NTS-DBLγ6 and VAR19-CIDRα1.1) diluted in 
PBS 0.2  % BSA. After 30  min of incubation on ice, the 
cell suspension was washed twice with PBS 0.2  % BSA 
and incubated for 30 min with a mouse anti-His antibody 
(QIAGEN), at 2  μg/ml in PBS 0.2  % BSA. The cell sus-
pension was washed twice and incubated for 30 min with 
PE-conjugated goat anti-mouse IgG (Beckman Coulter, 
diluted 1:100 in PBS 0.2  % BSA). Cells were fixed over-
night with PFA 4  % and washed twice with PBS. Data 
acquisition was performed using a BD FACScanto II flow 
cytometer (Becton–Dickinson, San Jose, CA, USA) and 
data were analysed using the FLOWJO 8.1 software (Tree 
Star Inc).
Surface plasmon resonance
The interaction between the EPCR and IT4-VAR19 
recombinant proteins was studied by surface plasmon 
resonance (SPR) using a Biacore X100 instrument (GE 
Healthcare). All experiments were performed in HBS-
EP buffer (GE Healthcare) at 25 °C. Recombinant EPCRH 
was immobilized on the analysis Fc2 channel of a CM5 
chip (GE Healthcare) by amine coupling to a total load-
ing of 1324 RU. Reference channel Fc1 was blocked with 
1 M ethanolamine-HCl pH 8.5 using the same chemistry. 
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IT4-VAR19 recombinant proteins were injected for 180 s 
with a dissociation time of 400  s. The highest concen-
tration was 1  µM for VAR19-NTS-DBLγ6 or 2  µM for 
VAR19-CIDRα1.1 and seven two-fold serial dilutions 
were also injected. Between the injections, the chip sur-
face was regenerated with a 60-s pulse of 10 mM NaOH. 
The specific binding response to EPCR was obtained by 
subtracting the response given by the analytes on Fc2 by 
the response on Fc1. The kinetic sensorgrams were fit-
ted to a global 1:1 interaction Langmuir model using the 
manufacturer’s software (Biacore X100).
Var gene transcriptional profiling
Var gene transcriptional profiling of IEs was performed 
as previously described [29]. In brief, total RNA was 
extracted from synchronized ring stage parasites ≤10-h 
post-invasion, using TRIzol (Invitrogen) as recom-
mended by the manufacturer. Total RNA was treated 
with TURBO DNase I (Ambion) to degrade contami-
nating DNA and cDNA was reverse transcribed using 
random hexamers and the SuperScript III First-Stand 
Synthesis System (Invitrogen). Five micrograms of 
starting total RNA were used to compare the full set of 
primers. Quantitative real-time PCR reactions were per-
formed on a CFX96 thermocycler (BioRad) in 20 µl using 
Advanced Universal SYBR Green Supermix (BioRad) and 
primer pairs specific for each IT4 var gene [29]. The rela-
tive transcription was determined by normalization with 
the housekeeping control gene seryl-tRNA synthetase 
[PlasmoDB: PF07_0073] and converted to relative copy 
numbers.
Adhesion assays
Adhesion assays on immobilized receptors were per-
formed as described [30]. Briefly, petri dishes (Falcon 
1058) with 0.5-cm diameter spots were coated over-
night at 4  °C with either 10 µl of PBS containing 50 µg/
ml recombinant human CD36 (R&D Systems), 50  µg/
ml recombinant human ICAM-1 (R&D Systems), 1 mg/
ml CSA sodium salt from bovine trachea (Sigma), 50 µg/
ml recombinant EPCR or 1  % BSA. After coating, the 
spots were washed with PBS and blocked with 20  µl of 
PBS 1  % BSA for 1  h at RT. After removing the block-
ing solution, the spots were washed twice with PBS and 
10 µl of purified IEs at trophozoite stage (25 × 106  IEs/
ml) were allowed to adhere. After incubating 1 h at RT, 
unbound IEs were washed away by adding 25 ml of PBS 
four times at the centre of the dish. Bound IEs were then 
fixed with 2  % glutaraldehyde in PBS for 2  h at RT. For 
each condition, the number of adherent IEs was counted 
microscopically using a Nikon Eclipse Ti microscope in 
five different fields of duplicated spots. Adhesion data 
presented in this study represent at least three independ-
ent experiments.
Inhibition assays of IEs on immobilized EPCR were 
carried out as described above with the exception of an 
additional pre-incubation step in which IEs were incu-
bated for 30  min at 37  °C with serial dilutions of puri-
fied anti-IT4-VAR19 antibodies (from 0.03 to 120 µg/ml) 
before being allowed to adhere to EPCR-coated spots. 
Binding inhibition was calculated as a percentage of 
adhesion compared to control spots where no anti-IT4-
VAR19 was added.
Adhesion assays of IEs on HBEC5i were carried 
out using a similar protocol as already described 
[12]. Briefly, HBEC-5i were cultured in 24 wells cul-
ture plates (0.4  ×  106  cells per well) 2  days before the 
assays and allowed to grow to confluency. Ten µl of IEs 
(1.5 × 106 IEs/ml) were pre-incubated with purified anti-
IT4-VAR19 antibodies (30 µg/ml) for 10 min at RT before 
being allowed to adhere to HBEC-5i-coated wells for 1 h 
at 37 °C. Unbound IEs were washed away by five washes 
with cell culture medium without serum. Cells were fixed 
with 1  % glutaraldehyde in PBS for 30  min and stained 
with Giemsa for 5 min. IE binding to HBEC-5i was ana-
lysed with a Nikon Eclipse Ti microscope.
Study populations
This cohort study was conducted during 2013 and 2014 
malaria transmission seasons (June to September and 
May to July, respectively) in Cotonou, Benin [21]. Children 
under 6 years of age admitted to Hôpital Mère-Enfant de la 
Lagune, Centre National Hospitalier Universitaire Hubert 
Koutoukou Maga and Hôpital Suru-Léré with malaria 
symptoms were screened using a rapid diagnostic test 
(DiaQuick Malaria P. falciparum Cassette, Dialab). Cer-
ebral malaria was defined as a microscopically confirmed 
P. falciparum infection and a Blantyre coma score ≤2, with 
no other known cause of coma. Severe malaria was defined 
as a P. falciparum infection presenting high parasitaemia 
levels (>250,000 parasites/μL) or severe anaemia (haemo-
globin level <5 g/dL). Uncomplicated malaria was defined, 
as described by WHO [31], by a P. falciparum infection 
accompanied with fever, headache or myalgia without 
signs of severity and/or evidence of vital organ dysfunc-
tion. Blood samples were collected when patients were 
admitted at the hospital and 30 days after. Children were 
treated according to Benin Ministry of Health guidelines.
Ethical statement
This study was approved by the Ethical Committee of 
the Research Institute of Applied Biomedical Sciences 
(CER-ISBA), Cotonou, Benin. Children were enrolled in 
this study after obtaining informed and written consent 
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from a parent or guardian, if they were diagnosed with 
either cerebral malarial, severe malaria or uncomplicated 
malaria.
Immune recognition assay
ELISA plates (Nunc) were coated with 50 µl per well of 
IT4-VAR19 recombinant proteins (VAR19-NTS-DBLγ6 
and VAR19-CIDRα1.1), AMA1 and VAR2CSA, at 1  µg/
ml diluted in PBS, and incubated at 4 °C overnight. After 
coating, the wells were blocked with PBS 4 % BSA, 100 µl 
per well, at 37  °C for 1  h. After removing the blocking 
solution, 50 µl of sera was added, diluted 1:50 in PBS 2 % 
BSA, and incubated at 37 °C for 1 h. The wells were then 
washed three times with 150  µl of PBS 0.5  % Tween20. 
IgG binding was detected with a HRP-conjugated anti-
human antibody (Jackson Immunoresearch), diluted 
1:4000 in PBS 2 % BSA. The plates were read at 655 nm 
after addition of 100 µl per well of TMB (3,3′,5,5′-tetra-
methylbenzidine) substrate (Biorad).
Statistical analyses
Optical density obtained by ELISA was converted into 
arbitrary units (AU) using the following formula: AU =   
100 × (LnODtest − LnODnegative sample)/(LnODpositive sample −  
LnODnegative sample) [32]. Negative and positive plasma 
samples were chosen based on their reactivity to AMA1 
already tested [33].
Results
Production of IT4‑VAR19 and EPCR recombinant proteins
The IT4-VAR19-DC8 cassette (VAR19-NTS-DBLγ6), 
composed of three DBL domains (DBLα2, DBLβ12 and 
DBLγ6) and a CIDR domain (CIDRα1.1), as well as the 
single VAR19-CIDRα1.1 domain, were produced as solu-
ble recombinant proteins (Fig. 1a, b).
His-tagged recombinant VAR19-NTS-DBLγ6 (197 kDa) 
was expressed in human embryonic kidney cells (HEK 
293F). After a two-step purification process, immobi-
lized metal ion affinity chromatography (IMAC) and gel 
filtration, an estimated yield of 1 mg of purified recom-
binant protein was recovered from a litre of HEK culture 
(Fig.  1b). SDS-PAGE analysis of VAR19-NTS-DBLγ6 
under non-reducing and reducing conditions revealed 
that a significant proportion of the recombinant protein 
was cleaved during the production phase. Indeed, even 
if Coomassie staining manifestly showed the presence of 
a single band at the expected apparent molecular weight 
under non-reducing conditions, two lower size extra 
bands (≈120 and ≈75  kDa) appeared under reducing 
conditions (Fig. 1b). These byproducts, which respective 
apparent molecular weights added up to one of the full 
length VAR19-NTS-DBLγ6, most likely resulted from 
a one-site cleavage, the protein fragments being held 
together by the presence of many predicted disulfide 
bonds in non-reducing conditions.
The recombinant his-tagged VAR19-CIDRα1.1 domain 
with an expected molecular weight of 20  kDa was 
expressed in E. coli SHuffle® cells and purified follow-
ing the same two-step process described above. The final 
production yield of VAR19-CIDRα1.1 was estimated at 
3.8 mg of purified recombinant protein per litre of bac-
teria culture. SDS-PAGE with subsequent gel staining 
with Coomassie revealed one single band at the expected 
molecular weight in reducing conditions whereas two 
close bands were visible in non-reducing conditions 
(Fig. 1b).
Recombinant proteins comprising the extracellular 
region of the human EPCR (24 kDa), with a 6× His tag 
at the C-terminus (EPCRH) or with an additional FLAG 
tag at the C-terminus (EPCRF-H) were also produced. 
Proteins were expressed in HEK 293F cells as soluble 
proteins with a production yield of 8.4 and 2.6  mg per 
litre of starting culture, respectively. SDS-PAGE analy-
sis of EPCR under non-reducing and reducing condi-
tions indicated that no proteolytic degradation occurred 
during production and purification processes (Fig.  1c). 
Under reducing conditions, EPCRH and EPCRF-H 
migrated slightly above their expected molecular weight 
(≈40  kDa). The recombinant proteins were therefore 
considered as suitable to carry on the study.
Kinetic binding analysis of EPCR‑IT4‑VAR19 interaction
The IT4-VAR19 recombinant proteins were subjected to 
SPR analysis to determine their affinity constants (KD) to 
recombinant EPCRH. The fitted kinetic data derived from 
the SPR sensorgrams revealed that recombinant VAR19-
NTS-DBLγ6 protein had a high affinity for recombinant 
EPCRH with a KD in the nanomolar range (KD = 52 nM) 
whereas the affinity of VAR19-CIDRα1.1 for EPCRH was 
much lower with a KD of 343 nM (Fig. 2a, b and Table 1).
Recombinant IT4‑VAR19 proteins specifically bind 
to human brain endothelial cells
The binding of the recombinant IT4-VAR19 proteins 
to human brain endothelial cells (HBEC5i cell line) 
was assessed. Endothelial cells were lifted from tissue 
culture dishes and incubated with IT4-VAR19 recom-
binant proteins. Flow cytometry analysis revealed 
that both VAR19-NTS-DBLγ6 and VAR19-CIDRα1.1 
bound to HBEC5i as reflected by a shift in fluores-
cence intensity compared to cells incubated with PBS 
alone (Fig.  2c). The VAR19-NTS-DBLγ6 and VAR19-
CIDRα1.1 binding to HBEC5i was evaluated using the 
same concentrations of soluble proteins (100  μg/ml). 
Considering the respective sizes (197 versus 20  kDa), 
VAR19-CIDRα1.1 was used in a ten-times excess 
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molarity compared to VAR19-NTS-DBLγ6. Even 
though these experimental conditions were favourable 
for VAR19-CIDRα1.1 to occupy more EPCR-binding 
sites at the surface of HBEC5i than for VAR19-NTS-
DBLγ6, the geometrical mean fluorescence intensity 
resulting from VAR19-NTS-DBLγ6 interactions with 
the endothelial cells was 14 times greater than that of 
VAR19-CIDRα1.1. Taken together, these results show 
that IT4-VAR19 binds to HBEC5i and that this bind-
ing involves, at least to some extent, VAR19-CIDRα1.1 
binding to EPCR.
Antibodies raised against VAR19‑NTS‑DBLγ6 are able 
to inhibit EPCR binding
Two rabbits were immunized with the VAR19-NTS-
DBLγ6 recombinant protein following a two-month 
schedule for a total of four injections. Antibody titres 
(IgG) at day 49 and day 63 were estimated by ELISA 
using the immunizing protein as target antigen (Addi-
tional file 1). VAR19-NTS-DBLγ6 appeared to be a highly 
immunogenic antigen as reflected by the very elevated 
antibody titres obtained for the two rabbits as early as 
day 49 (787,000 and 809,000). The pre-immune sera of 
both animals did not react with the recombinant protein 
used for immunization.
To evaluate the ability of these antibodies to inhibit 
recombinant IT4-VAR19 proteins adhesion to EPCRH, 
purified rabbit IgG were tested in protein binding inhi-
bition assays. Purified IgG from both rabbits were able 
to inhibit the adhesion of recombinant VAR19-NTS-
DBLγ6 protein to EPCRH in a dose-dependent manner 
(Additional file 2). The inhibiting properties of IgG issued 
from the two different rabbits were similar even if a 10 % 
increased inhibition was obtained with IgG from rabbit 
IT4-VAR19 FL (350 kDa)
IT4-VAR19-NTS-DBLγ6 (197 kDa)
IT4-VAR19-CIDRα1.1 (20 kDa)
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cb
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Fig. 1 Recombinant proteins expressed in HEK293 cells. a Representation of IT4‑VAR19 domain organization and sequence limits of the full‑length 
IT4‑VAR19 and the recombinant IT4‑VAR19 domains studied (VAR19‑NTS‑DBLɣ6 and CIDRα1.1). IT4‑VAR19 is composed of five Duffy‑binding‑like 
domains (shown in green), two cysteine‑rich interdomain regions (shown in red), a transmembrane segment and an acidic C terminus sequence 
(ATS, shown in blue). b SDS‑PAGE under reducing and non‑reducing conditions of purified VAR19‑NTS‑DBLɣ6 and CIDRα1.1. c SDS‑PAGE under 
reducing and non‑reducing conditions of purified recombinant EPCR proteins (His tagged EPCRH and His/FLAG tagged EPCRF+H)
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2 at the highest concentration tested. Purified IgG from 
pre-immune sera had no inhibitory activity. IgG purified 
from the immune serum of rabbit 2 will be used through-
out the rest of study and will be referred as anti-VAR19 
IgG.
Selection of IEs on anti‑VAR19 antibodies, EPCR 
and HBEC5i cells
Erythrocytes infected with the FCR3 (IT4) parasite 
strain, formerly selected for CSA-binding (FCR3-CSA) 
and therefore expressing VAR2CSA, were selected by 
successive panning on anti-VAR19 IgG, recombinant 
EPCR or HBEC5i cells. Panning was pursued until the 
same var gene transcription profile was observed in two 
consecutive panning rounds.
FCR3-CSA, panned for three rounds on anti-IT4-
VAR19 IgG (Fig.  3a) express a highly diverse mixture 
of var transcripts from different groups including the 
IT4var19 (15 %).
After seven rounds of panning on anti-VAR19 IgG, a 
population, referred to as FCR3-VAR19, was selected. In 
FCR3-VAR19, 95 % of IEs expressed the IT4var19 tran-
script, 1  % the ITvar34 and 1  % the ITvar14 transcript, 
the remaining 3  % of the population expressing a panel 
of other var transcripts. The detailed var gene expres-
sion profiles of infected erythrocytes panned three times 
and seven times are depicted in Fig. 3a, b and Additional 
file 3A and B, reflecting the progressive enrichment of IEs 
expressed the IT4var19 transcript.
The selected FCR3-VAR19 IEs were then reselected on 
human brain endothelial cells (HBEC5i). After two and 
three panning rounds, the same var gene transcription 
profile was observed in which 82 % of IEs expressed the 
IT4var19 transcript (Fig. 3c and Additional file 3D). This 
selected population of IEs is referred to as FCR3-HBEC5i. 
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Fig. 2 Recombinant IT4‑VAR19 proteins bind specifically to EPCR and human brain endothelial cells. a, b Sensorgram showing interaction between 
IT4‑VAR19 proteins and EPCR. Recombinant EPCR protein was immobilized on a chip and recombinant IT4‑VAR19 proteins were injected at eight 
different concentrations from 1 µM to 7.8 nM for VAR19‑NTS‑DBLɣ6 (a) and 2 µM to 15.6 nM for CIDRα1.1 (b). Using the manufacturer’s software, a 
Langmuir model for a 1:1 interaction was chosen to evaluate the data and determine the KD constants. c Binding assay of the IT4‑VAR19 proteins 
(NTS‑DBLɣ6 and CIDRα1.1) to HBEC5i by flow cytometry. HBEC5i cells were incubated with recombinant IT4‑VAR19 proteins and binding was 
detected using a mouse anti‑His IgG and a PE‑conjugated anti‑mouse IgG
Table 1 Affinity constants reflecting the binding of IT4VAR19 
recombinant proteins to EPCR
kon (M
−1s−1) koff (s
−1) KD (M)
NTS‑DBLɣ6 2.2E+04 1.1E−03 5.2E−08
CIDRα1.1 3.5 E+04 1.2E−02 3.4E−07
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FCR3-HBEC5i IEs also expressed a mixture of group B 
var transcripts (2  % IT4var14 (DC17), 2  % IT4var24 as 
well as 2 % of the group C IT4var34 transcript).
In a second set of experiments, FCR3-CSA, panned 
for three rounds on anti-VAR19 IgG (Fig. 3a) was subse-
quently selected on recombinant EPCRH. Following six 
extra rounds of panning on EPCRH, a population contain-
ing 58 % of IEs expressing IT4var19 transcript was selected 
(Fig. 3d and Additional file 3C). This selected population of 
IEs, referred to as FCR3-EPCR IEs, also expressed a mix-
ture of group B var transcripts (16 % IT4var14 (DC17), 3 % 
IT4var24, 3 % IT4var25) as well as 3 % of the group B/A 
IT4var6 transcript, a var gene that encodes for a PfEMP1 
possessing, as IT4-VAR19, a DC8 domain cassette.
Adhesion phenotype of selected IEs
Static binding assays, using recombinant proteins or sug-
ars coated on plastic (CD36, ICAM-1, EPCRH or CSA), 
were performed to determine the binding phenotype of 
FCR3-VAR19, FCR3-EPCR and FCR3-HBEC5i IEs. The 
former erythrocyte population FCR3-CSA, known to 
adhere to CSA and not to any other receptors, was also 
included in the assay as a reference. The three selected 
IE populations revealed a strong binding to EPCRH 
(Fig. 4a) and much lower adhesion to other host cytoad-
hesion receptors (CD36, ICAM1 and CSA). Importantly, 
by comparison to other selected IE populations, ICAM1 
binding was higher in the FCR3-HBEC5i IE population. 
For each IE population, the var transcript profile was 
verified the day before the adhesion phenotypes were 
assessed (Fig. 4b).
Flow cytometry experiments showed that FCR3-
VAR19, FCR3-EPCR and FCR3-HBEC5i IEs were highly 
recognized by anti-VAR19 IgG whereas the control IE 
population FCR3-CSA was not (Fig. 4c). Anti-VAR2CSA 
antibodies, recognizing FCR3-CSA, did not react with any 
of the newly selected IE populations. Unlike for FCR3-
CSA, neither FCR3-VAR19, FCR3-EPCR nor FCR3-
HBEC5i IEs were able to fix non-immune IgM.
In a qualitative analysis, anti-IT4-VAR19 IgG staining 
of FCR3-VAR19 IEs revealed a dotty fluorescence pattern 
associated to the red cell membrane (Fig. 4d), similar to 
those obtained when targeting other PfEMP1 proteins 
expressed at the IE surface [34].
FCR3-VAR19 FCR3-HBEC5i
FCR3-EPCR
6 rounds of
panning on EPCR
4 rounds of 
panning on an-VAR19
FCR3 aer 3  panning 
on an-VAR19
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Fig. 3 Transcriptional analysis of var genes expressed after panning IEs anti‑IT4‑VAR19 antibodies (a, b), HBEC5i (c) and with EPCR (d). Var genes are 
organized by group: group A in pink, group B/A in red, group B in green, group C in blue. Results were normalized with the control housekeeping 
gene seryl‑tRNA synthetase (PF07_0073). The percentage of each var transcript is shown as pie charts
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VAR19‑NTS‑DBLɣ6 antibodies inhibits the adhesion 
of FCR3‑VAR19 and FCR3‑EPCR IEs to EPCR
The capacity of anti-VAR19 antibodies to inhibit the 
adhesion of FCR3-VAR19 and FCR3-EPCR IEs to EPCRH 
was evaluated. A static binding inhibition assay where 
recombinant EPCRH was immobilized on plastic, revealed 
that anti-VAR19 antibodies were able to inhibit the adhe-
sion of FCR3-VAR19 and FCR3-EPCR IEs to EPCRH, in 
a dose-dependent manner (Fig.  5a). FCR3-VAR19 bind-
ing to EPCR was inhibited to a higher extent than FCR3-
EPCR binding at low antibody concentrations.
VAR19‑NTS‑DBLɣ6 antibodies partially inhibit the 
adhesion of FCR3‑VAR19 and FCR3‑EPCR IEs to HBECs
Both FCR3-VAR19 and FCR3-EPCR IEs were able to 
adhere to HBECs in static binding assays (Fig.  5b). No 
(See figure on previous page.) 
Fig. 4 a Adhesion profile of IEs selected with anti‑VAR19 antibodies (FCR3‑VAR19), EPCR (FCR3‑EPCR) and human brain endothelial cells (FCR3‑
HBEC5i). Data shown is the mean number of IEs per mm2 adhering to receptors coated on plastic Petri dishes, as determined in three independent 
assays in duplicated spots (error bars represents the standard deviation). b Transcription analysis of var genes expressed at the same parasite cycle as 
the adhesion assays were done. c Flow cytometry analysis of IEs obtained after panning labelled with rabbit anti‑VAR19, anti‑VAR2CSA and mouse 
anti‑IgM antibodies (blue histograms) compared to negative control (without primary antibody, red histograms). d Immunofluorescence assay of 
FCR3‑VAR19 IEs stained with rabbit anti‑VAR19 IgG (red). The parasite nucleus is stained with Hoechst 3342 (blue)
a
cb
IE
Fig. 5 Static inhibition assay of IEs on immobilized EPCR and human brain endothelial cells. a Adhesion inhibition assays on EPCR‑coated plastic 
spots were performed using FCR3‑VAR19 and FCR3‑EPCR IEs pre‑incubated with anti‑VAR19 antibodies at different concentrations (ranging from 
0.03 to120 µg/ml). The percentage of inhibition was calculated using the number of IEs obtained after pre‑incubation with PBS alone as a reference. 
Error bars represent the standard deviation of three independent experiments. b Adhesion of FCR3‑VAR19, FCR3‑EPCR and FCR3‑CSA IEs to HBEC5i 
cells in the presence or absence of anti‑VAR19 antibodies is shown. Arrows points to adherent IEs. c Mean number of IEs adhering per 100 HBEC5i 
cells was determined in two independent assays (error bars represents the standard deviation). The percentage of inhibition was calculated using 
the number of IEs obtained after pre‑incubation with PBS alone (no IgG) as a reference
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binding of FCR3-CSA IEs was observed on HBEC5i. 
In order to evaluate the capability of antibodies raised 
against VAR19-NTS-DBLɣ6 to interfere with FCR3-
VAR19 and FCR3-EPCR IE binding to HBEC5i cells, both 
selected IE populations were pre-incubated with 30 µg/ml 
of antibody before being allowed to interact with a mon-
olayer of endothelial cells. Anti-VAR19 IgG were able to 
partially inhibit the binding of FCR3-VAR19 (85 % inhibi-
tion) and FCR3-EPCR (79 % inhibition) IEs (Fig. 5c).
IT4‑VAR19‑DC8 cassette and CIDRα1.1 are not associated 
with increased recognition of convalescent‑phase sera 
from Beninese children
The evaluation of the antigenic relationship of DC8-
PfEMP1 variants, was assessed by quantifying the levels of 
naturally acquired antibody targeting the IT4-VAR19 full-
length DC8 cassette, the single EPCR-binding CIDRα1.1 
domain, the apical membrane antigen (AMA)-1 and full 
length VAR2CSA extracellular region, in plasma sam-
ples from Beninese children presenting either acute mild 
malaria (UM), severe malaria (SM) or cerebral malaria 
(CM) at the time of their admission to the clinic and 
from convalescent-phase sera collected 30 days after anti-
malaria treatment (Fig. 6). In a first analysis, no significant 
difference in immune recognition was observed between 
the SM and UM groups, for all the recombinant proteins 
tested. It was therefore decided to combine and compare 
those two groups (SM/UM) with the CM group alone. 
Interestingly, children with CM had significantly higher 
levels of IgG towards all the different antigens examined 
compared to the SM/UM group at day 0 (p values <0.05) 
but not at day 30. Surprisingly, no significant difference in 
the levels of antibodies towards IT4-VAR19 antigens was 
observed in both groups between plasma samples col-
lected during the acute malaria phase compared to sam-
ples collected 30 days after anti-malaria treatment.
Discussion
The human EPCR, which is the cellular receptor for pro-
tein C, is expressed by a variety of endothelial cells as a 
membrane-associated protein but also exists as a solu-
ble form, displaying multiple and important physiologi-
cal functions [18]. The 1 TM (trans-membrane domain) 
EPCR is a glycosylated protein that possesses two cysteines 
(C118–C186) engaged in a disulfide bond [35]. This article 
describes a method of expression of the EPCR topological 
domain (aa 18–210) in a human-based system supporting 
type I N-glycolsylation and disulfide bond formation as 
well as an efficient two-step purification procedure. The 
qualitative analysis of the two differently tagged versions of 
EPCR revealed that the recombinant proteins most likely 
exhibit the structural and functional features similar to 
that of native EPCR. Recombinant EPCRH and EPCRF-H 
migrated on SDS-PAGE to an apparent molecular weight 
of ≈40 kDa, higher than their theoretical weights of 23.7 
and 24.7 kDa, respectively (Fig. 2). This is consistent with 
the fact that post-translational modifications, such as the 
four expected N-glycosylations (positions 47, 64, 136, 172), 
occurred during the expression process.
Turner et  al. provided the first experimental evidence 
that a DC8 cassette-carrying PfEMP1 (IT4-VAR20), pro-
duced as a full-length recombinant protein, was able to 
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Fig. 6 Antibody levels to IT4‑VAR19 proteins (NTS‑DBLɣ6 and CIDRα1.1), VAR2CSA and AMA1 in the plasma of children from Benin presenting with 
cerebral malaria (CM, N = 18) or with severe or uncomplicated malaria (SM/UM, N = 34) attack. Plasma samples were collected at admission (day 0) 
and 30 days later (day 30)
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bind to EPCR with high affinity [15], this binding being 
only mediated by the CIDRα1.1 single domain. Despite 
extensive sequence diversity, CIDR domains belonging to 
the DC8 and DC13 cassettes appear to retain their ability 
to bind to EPCR [16, 36] with some reported exceptions, 
such as the DC8-CIDRα1.6 [PlasmoDB: PF08_0140] of 
the 3D7 parasite strain [15].
This work shows that the multi-domain VAR19-NTS-
DBLγ6 binds to EPCR with a greater affinity than the 
CIDRα1.1 domain alone (Figs. 2, 3). Indeed, the KD of 52 nM 
reflecting the affinity of VAR19-NTS-DBL3γ for EPCR is 
almost seven times lower than that of the CIDRα1.1 domain 
alone (KD = 343 nM). The only other study comparing the 
affinity for EPCR binding of a DC8-type multi-domain con-
struct (full length IT4-VAR20) and the corresponding CIDR 
domain alone with the same experimental settings, reported 
dissociation constants of 10  nM and 29  nM, respectively 
[15]. The lower observed affinity could be due to the fact 
that the CIDRα1.1 construct used in this study was slightly 
shorter than previously published [12, 36].
This work also demonstrates that VAR19-NTS-DBLγ6 
binding to the EPCR-expressing endothelial cell line 
(HBEC5i) is more pronounced than that of the CIDRα1.1 
domain alone (Fig. 2). This is consistent with our previ-
ous observation with EPCR (Fig.  3). In addition, recent 
data showed that all seven individual domains of IT4-
VAR19, including CIDRα1.1, were able to bind to diverse 
endothelial cells [16]. Therefore, the binding of VAR19-
NTS-DBLγ6 to HBEC5i may result from (i) interactions 
of CIDRα1.1 with EPCR, and from (ii) synergic interac-
tions from other domains (DBLα2, DBLβ12, DBLγ6) with 
(one) other, yet unknown, cellular receptor(s). In this con-
text, the var gene expression profiles of IEs after selection 
on either anti-VAR19 antibodies (raised against VAR19-
NTS-DBLγ6), recombinant EPCR or HBEC5i cells was 
assessed. After panning with anti-VAR19 IgG, an homog-
enous IE population (95 %) expressing the IT4var19 tran-
script (FCR3-VAR19) was obtained, whereas selection on 
EPCR led to a more heterogeneous population express-
ing IT4var19 (58 %) but also a variety of other var genes 
belonging to the group B IT4var14, IT4var24, IT4var25 
displaying other domain cassette types than DC8 or 
DC13 (Fig.  3). IT4-VAR19 represent the preferentially 
expressed PfEMP1 when FCR3 IEs are selected based 
on their capability to bind EPCR. No significant popu-
lation of IEs expressing the EPCR-binding IT4-VAR20 
PfEMP1 (<1  %) was found. Furthermore, only 3  % of 
FCR3-EPCR IEs were expressing the EPCR-binding IT4-
VAR06 PfEMP1. However, a significant proportion of IEs 
(16 %) expressing IT4-VAR14-DC17 were selected upon 
panning to EPCR. Interestingly, IT4-VAR14 possesses a 
CD36-binding CIDRα5 and an ICAM-1-binding DBLβ 
type [37] and was previously reported to weakly bind 
EPCR when binding was assessed using the CIDR1α5 
domain alone [15]. Furthermore, IT4-VAR14-DC17 
IEs had weak binding to the immortalized human brain 
microvascular endothelial cell line (THBMEC) relative 
to IT4-VAR19 [12]. Taken together, these results may 
suggest that IT4-VAR14-DC17 IEs can bind to EPCR 
and endothelial cells even though this PfEMP1 variant 
possesses a CD36-binding CIDRα5. Interestingly, no 
major change of transcription profile was found after 
three rounds of panning of the FCR3-VAR19 popula-
tion on HBEC5i endothelial cells. By comparison to the 
study by Claessens et al. [13], the IT4var07 gene was not 
upregulated after three pannings on HBEC5i cells. The 
three selected IE populations revealed a strong binding 
to EPCR (Fig.  4a) and a much lower adhesion to other 
host receptors (CD36, ICAM1 and CSA). Taken together, 
these results indicate that IT4-VAR19 is the preferentially 
selected EPCR binding PfEMP1 from the IT4 strain.
Antibodies raised against VAR19-NTS-DBLɣ6 DC8 
cassette were able to fully inhibit the adhesion of FCR3-
VAR19 and FCR3-EPCR IEs to EPCR, in a dose-depend-
ent manner (Fig. 5a) but partially inhibit the adhesion of 
FCR3-VAR19 and FCR3-EPCR IEs to HBEC5i (Fig.  5c). 
These results suggest that the adhesion of these parasite 
lines is largely dependent on EPCR interaction but that 
other interactions involving other PfEMP1 domains than 
CIDRα1.1, with as yet unidentified host receptors, are 
involved in the adhesion to endothelial cells. Further-
more, as only 50  % of the FCR3-EPCR IEs population 
express IT4var19 transcript (Fig. 4b), it is likely that the 
sera raised against VAR19-NTS-DBLɣ6 DC8 cassette 
cross-reacted with the other EPCR binding variants.
The evaluation of the role of IT4-VAR19-like EPCR 
binding parasites in severe childhood infections was 
assesses by quantifying the levels of naturally acquired 
antibody to the IT4-VAR19 recombinant proteins 
in plasma samples from Beninese children, present-
ing either UM, SM or CM. No difference in the plasma 
level of antibodies was observed between VAR2CSA and 
VAR19 antigens. Only antibodies to VAR19-NTS-DBLɣ6 
slightly, although not significantly, increased between 
admission and convalescence. These results suggest that 
children did not develop humoral immunity against the 
IT4-VAR19 DC8 cassette and therefore that PfEMP1s 
expressed by IEs infecting children in Benin are antigeni-
cally distinct from IT4-VAR19 DC8 cassette. Although 
recent evidence indicates that parasites expressing DC8 
and DC13 domain cassettes are increased in severe pae-
diatric malaria infections [14, 38], further studies are 
needed to validate the exact role of both domain cas-
settes in severe malaria conditions, and how immunity 
develops against those variant antigens. Surprisingly the 
pregnancy associated malaria antigen VAR2CSA was 
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also recognized by children sera although this var gene is 
supposed to be only expressed during placental malaria. 
It was previously reported in different studies that spe-
cific IgG against VAR2CSA are present at significant 
levels among some men and children [39, 40], suggest-
ing that exposure to these variants is not exclusive to 
pregnancy. Although the level and prevalence of reactiv-
ity to VAR2CSA is significantly higher in pregnant mul-
tigravid women, the reactivity in plasma from children 
emphasizes our incomplete understanding of the pro-
tective immune response during placental malaria and 
childhood. Further investigations are needed to assess 
the exact role of VAR2CSA in severe malaria pathogen-
esis and immunity. Finally, the only significant difference 
observed was that children with CM had significantly 
higher levels of IgG to all antigens examined compared to 
SM/UM children. This result confirms previous observa-
tions that children with CM are distinguished by higher 
antibody levels to all antigens tested [41].
Conclusions
These data indicate that IT4-VAR19 is the preferentially 
selected IT4-EPCR-binding PfEMP1 but that humoral 
immunity against the EPCR-binding VAR19-DC8 cas-
sette or the CIDRα1.1 domain is not boosted during a 
single episode of severe malaria in Benin.
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